Drug news
FDA approves Ultresa and Viokace (Aptalis Pharma) for Exocrine Pancreatic Insufficiency
Aptalis Pharma received FDA approval on 1 March 2012 to market Ultresa (pancrelipase) and Viokace (pancrelipase) to treat Exocrine Pancreatic Insufficiency (EPI), a condition in which the body is unable to properly digest fat, protein and carbohydrates and absorb nutrients.Ultresa is specifically indicated as a treatment for EPI in adults and children due to Cystic Fibrosis or other conditions, while Viokace, in combination with a proton-pump inhibitor, is indicated in adults to treat EPI due to Chronic Pancreatitis or Pancreatectomy.